ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth

ElevateBio, LLC announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by Matrix Capital Management, and joined by a leading group of new and existing investors.

  • Proceeds enable expansion and scale of ElevateBio’s cell and gene technology platforms, end-to-end capabilities, and therapeutic pipeline to serve an increasing number of biopharmaceutical partners and drive revenue growth
  • ElevateBio has added more than 15 new biopharma partners across its ecosystem over the past year, including strategic gene editing collaborations with Moderna and Novo Nordisk
  • ElevateBio has advanced its technology platforms, including expansion of gene editing systems and demonstration of multiplex base editing, enabling the development of a broad array of in vivo and ex vivo therapeutics
  • Series D led by AyurMaya Capital Management, a new fund managed by Matrix Capital, and joined by Woodline, Lee Family Office, Novo Nordisk, with continuing support by existing investors
  • In connection with the financing, Khalil Barrage from The Invus Group has joined ElevateBio’s Board of Directors

WALTHAM, Mass.--(BUSINESS WIRE)-- ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming cell and gene therapies, today announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by Matrix Capital Management, and joined by a leading group of new and existing investors. ElevateBio’s syndicate now includes new investors Woodline, Lee Family Office (Asia), and R&D partner Novo Nordisk, as well as existing investors: Matrix Capital Management, The Invus Group, Emerson Collective, SoftBank Vision Fund 2, Fidelity Management & Research Company, MPM Capital, F2 Ventures, Redmile Group, EcoR1 Capital, Samsara BioCapital, Surveyor Capital (a Citadel company), EDBI, Vertex Ventures, iTochu, and a large institutional investor. In connection with the financing, Khalil Barrage, Managing Director of The Invus Group, was appointed to ElevateBio’s Board of Directors.

“We have made significant strides in scaling our technologies and end-to-end capabilities in our pursuit to become the world’s most indispensable cell and gene therapy technology company. We are thrilled to welcome Khalil to our Board as his expertise will be invaluable as the number of strategic partners harnessing the power of our integrated ecosystem continues to grow,” said David Hallal, Chairman and Chief Executive Officer of ElevateBio. “We’re emboldened by the pace of advancements to our technology platforms and continue to drive innovation from concept through commercialization and redefine how companies operate, how products are created, and how disease is treated.”

Proceeds from the financing will be used to further advance the company’s technology platforms – Life Edit gene editing, induced pluripotent stem cells (iPSCs), and RNA, cell, protein, vector engineering – and BaseCamp®, its end-to-end genetic medicine current Good Manufacturing Practice (cGMP) manufacturing and process development business, to accelerate the design, manufacturing, and development of cell and gene therapies. The funding will also support ElevateBio’s continued efforts to expand its geographic reach and increase its cGMP manufacturing capacity to provide its academic and industry partners with turnkey and scalable access to technologies and services across the full-product lifecycle.

In connection with Novo Nordisk’s investment in the Series D financing, ElevateBio’s integrated subsidiary Life Edit Therapeutics also announced a multi-target collaboration with Novo Nordisk to discover and develop base editing therapies. In addition to the equity investment, Life Edit will receive an upfront cash payment and is eligible to receive potential development, regulatory, and commercial milestones of $250-$335 million for each of the seven programs under the collaboration. Life Edit also has an option to opt into a global profit share for one program. The collaboration underscores ElevateBio’s strategy to form new industry partnerships where the company’s technology is at the foundation, while selectively advancing its own portfolio of genetic medicines.

“ElevateBio has created a truly disruptive business model with integrated technologies, capabilities, and capacity for which we see accelerating need as the complexity of cell and gene therapies continues to grow,” said Khalil Barrage, Managing Director at The Invus Group. “In this still-nascent industry, we believe ElevateBio is looking several steps ahead to pave the path for partners across the biopharmaceutical industry to accelerate innovation and bridge the gap between discovery and widespread delivery of cell and gene therapies as everyday medicine.”

Since its previous financing round in 2021, ElevateBio has supercharged its gene editing capabilities through the acquisition, integration, and growth of Life Edit’s novel RGN and base editing technologies, leading to multiple partnerships, including the recently announced collaborations with Moderna Therapeutics and Novo Nordisk. ElevateBio has also expanded access to its iPSC platform technology through a partnership with the California Institute for Regenerative Medicine and the formation of a new company aimed at developing iPSC-derived allogeneic immune cell therapies. The company has also increased BaseCamp manufacturing and process development capabilities to support a growing number of cell and gene therapy innovators.

About ElevateBio:
ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company’s integrated technologies model offers turnkey scale and biotechnological capabilities to power cell and gene therapy processes, programs and companies to their full potential. The ElevateBio ecosystem combines multiple R&D technology platforms – including Life Edit, a next-generation, full-spectrum gene-editing platform; a proprietary induced pluripotent stem cell (iPSC) platform, and an RNA, cell, protein, and vector engineering platform – with BaseCamp®, its end-to-end genetic medicine cGMP manufacturing and process development business, to power the discovery and development of advanced therapeutics.

In addition to enabling a broad breadth of biopharmaceutical companies in the development of their novel cell and gene therapies, ElevateBio is also building a highly innovative pipeline of cellular, genetic, and regenerative medicines. ElevateBio aims to be the dominant engine inside the world’s greatest scientific advancements harnessing human cells and genes to alter disease. For more, visit www.elevate.bio or follow ElevateBio on LinkedIn or Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005070/en/


Investor contact:
Catherine Hu

Media contact:
DJ Webster

Source: ElevateBio, LLC

Powered by Business Wire

View this news release online at: